Seghatol Frank F, Shah Dipan J, Diluzio Silvia, Bello David, Johnson Maryl R, Cotts William G, O'Donohue Jenny A, Bonow Robert O, Gheorghiade Mihai, Rigolin Vera H
Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Am J Cardiol. 2004 Apr 1;93(7):854-9. doi: 10.1016/j.amjcard.2003.12.023.
Beta blockers improve left ventricular (LV) ejection fraction but patient responses are heterogenous. We investigated the role of contractile reserve (CR) in predicting beta-blocker response in ischemic and nonischemic cardiomyopathy. Resting and low-dose dobutamine echocardiograms were recorded in 32 patients with heart failure (LV ejection fraction <or=35%), 18 with ischemic cardiomyopathy (IC), and 14 with idiopathic dilated cardiomyopathy (IDC). A segment was defined as CR positive (CR+) or negative (CR-) based on response to dobutamine. Patients were then classified as CR+ or CR- based on number of improved segments (IC group) or ejection fraction improvement (IDC group) in response to dobutamine. During follow-up (2, 6, and 14 months after beta-blocker initiation), response was measured by the percent of segments showing improved contractility from baseline, ejection fraction, and wall motion score index. In the IC group, the percent of improved segments was greater at 2 and 6 months in CR+ versus CR- (70% vs 15% and 39% vs 17%, p <0.05), whereas it was greater at all periods in the patients with IDC (36% vs 9% at 2 months, 50% vs 19% at 6 months, and 63% vs 42% at 14 months, p <0.05). Findings for ejection fraction and wall motion score index were similar. Therefore, time course and magnitude of improvement in LV function in patients with heart failure receiving beta blockers are related to CR status. CR predicts a greater early response in IC, whereas it predicts a greater response at all time periods in IDC. However, even patients without CR showed improvement in LV function at 14 months.
β受体阻滞剂可改善左心室(LV)射血分数,但患者的反应存在异质性。我们研究了收缩储备(CR)在预测缺血性和非缺血性心肌病患者对β受体阻滞剂反应中的作用。对32例心力衰竭患者(左心室射血分数≤35%)进行了静息和小剂量多巴酚丁胺超声心动图检查,其中18例为缺血性心肌病(IC),14例为特发性扩张型心肌病(IDC)。根据对多巴酚丁胺的反应,将节段定义为CR阳性(CR+)或阴性(CR-)。然后根据多巴酚丁胺反应后改善节段的数量(IC组)或射血分数的改善情况(IDC组)将患者分为CR+或CR-。在随访期间(开始使用β受体阻滞剂后2、6和14个月),通过与基线相比显示收缩力改善的节段百分比、射血分数和壁运动评分指数来衡量反应。在IC组中,CR+组在2个月和6个月时改善节段的百分比高于CR-组(70%对15%,39%对17%,p<0.05),而在IDC患者中,所有时间段改善节段的百分比均更高(2个月时36%对9%,6个月时50%对19%,14个月时63%对42%,p<0.05)。射血分数和壁运动评分指数的结果相似。因此,接受β受体阻滞剂治疗的心力衰竭患者左心室功能改善的时间进程和幅度与CR状态有关。CR预测IC患者早期反应更大,而在IDC患者中,CR预测所有时间段反应更大。然而,即使没有CR的患者在14个月时左心室功能也有所改善。